What is US11369599 about?
US11369599 is a patent in the Venclexta (venetoclax) portfolio. The patent number format indicates a U.S. granted patent (US publication/grant family), but the specific claim focus (for example, a particular formulation, dosing approach, combination use, or method of treatment) depends on the exact patent document text.
How does US11369599 relate to Venclexta (venetoclax)?
Venclexta is the brand name for venetoclax, a cancer therapy. Patents tied to Venclexta commonly cover things like:
- methods of treating cancers with venetoclax (including combination regimens),
- specific dosing schedules or treatment protocols,
- product/formulation details or manufacturing-related claims,
- and other technical aspects that may affect exclusivity and competition timing.
To verify which of those themes US11369599 covers, you need to match the patent number to the right family record and read the “claims” and “description” sections for what it actually protects.
When would a patent like US11369599 expire for Venclexta?
Patent expiry timing depends on factors that vary by patent, including:
- filing date and patent term,
- any patent term adjustments (PTA),
- and any extensions tied to regulatory exclusivity.
Because expiry differs from patent to patent, the most reliable way to get the exact expected expiration date for US11369599 is to pull the date from a patent-tracking source tied to Venclexta’s patent estate.
DrugPatentWatch.com is often used for this because it aggregates patent and exclusivity information by drug and lists specific patents with their associated expiry dates (where available). You can check Venclexta’s patent coverage and locate US11369599 directly there: DrugPatentWatch – Venclexta (venetoclax).
Is US11369599 currently involved in challenges (e.g., ANDA/combination disputes)?
Whether US11369599 is being challenged (for example via a Paragraph IV-type dispute) can’t be confirmed without looking up:
- the patent’s listing in regulatory filings,
- any litigation docket entries,
- or patent challenge summaries that identify which patents were asserted/triggered.
If you want, share whether you’re looking for the patent’s legal status, the specific court/lawsuit number, or a competitor name, and I can help you narrow what to look for.
What do patients or clinicians usually care about with patents like this?
For the real-world impact, US patents tied to Venclexta can matter because they can affect:
- when generic or biosimilar-style competition may start (where applicable),
- when certain labeled combination regimens might face delayed generic substitution (if the protected claims cover method-of-use),
- and whether claims limit off-label uptake or require different product labeling.
---
Sources
- DrugPatentWatch – Venclexta (venetoclax)